Financing ·
Elicio Therapeutics, Inc. entered into a Securities Purchase Agreement on July 1, 2026, to issue and sell 4,380,313…
ELTXElicio Therapeutics, Inc.
Elicio Therapeutics, Inc. entered into a Securities Purchase Agreement on July 1, 2026, to issue and sell 4,380,313 shares of common stock at $3.43 per share in a registered direct offering to institutional investors. The offering is expected to close on July 6, 2026, and is expected to generate approximately $15 million in gross proceeds. Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments.